[ET Net News Agency, 15 September 2021] CStone Pharmaceuticals (02616) said the
investigational new drug (IND) application of multi-specific antibody CS2006/NM21-1480 has
been approved by the National Medical Products Administration (NMPA) of China.
CS2006/NM21-1480 represents a leading class of next-generation anti-PD-1/PD-L1 cancer
immunotherapies and a new backbone molecule for combinations. It is a monovalent,
tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin
(HSA).(RC)